[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-ai-drug-discovery":3},{"tag":4,"articles":10},{"id":5,"name":6,"slug":7,"article_count":8,"description_zh":9,"description_en":9},"c8d6ba30-0777-4435-af36-c4aaafc71198","AI drug discovery","ai-drug-discovery",0,null,[11,20],{"id":12,"slug":13,"title":14,"summary":15,"category":16,"image_url":17,"cover_image":17,"language":18,"created_at":19},"a7804aaf-0ac7-406f-818e-1faceaae20c6","why-reid-hoffman-leaving-microsoft-board-matters-en","Why Reid Hoffman leaving Microsoft’s board matters more than his titl…","Reid Hoffman’s exit from Microsoft’s board is a bet on focused founder control in AI drug discovery.","industry","https:\u002F\u002Fxxdpdyhzhpamafnrdkyq.supabase.co\u002Fstorage\u002Fv1\u002Fobject\u002Fpublic\u002Fcovers\u002Finline-1780828373734-jwy1.png","en","2026-06-07T10:32:22.634004+00:00",{"id":21,"slug":22,"title":23,"summary":24,"category":25,"image_url":26,"cover_image":26,"language":18,"created_at":27},"487edd3a-bc1d-4a3b-af82-b304fcb024f6","reid-hoffman-leaves-microsoft-board-manus-ai-en","Reid Hoffman leaves Microsoft board for Manus AI","Reid Hoffman is leaving Microsoft’s board after nearly a decade to focus on Manus, his AI drug discovery startup with $50M+ raised.","ai-agent","https:\u002F\u002Fxxdpdyhzhpamafnrdkyq.supabase.co\u002Fstorage\u002Fv1\u002Fobject\u002Fpublic\u002Fcovers\u002Finline-1780827472278-elag.png","2026-06-07T10:17:21.75719+00:00"]